Edwards Lifesciences has CE-marked for sale in Europe two heart valve therapy products - the Carpentier-Edwards PERIMOUNT Magna bioprosthesis and the Edwards MC3 tricuspid annuloplasty system. The PERIMOUNT Magna valve is the first pericardial heart valve specifically designed to optimise haemodynamics for an individual patient's anatomy, claims the Irvine, California firm. The MC3 device, the company adds, features a first-of-its-kind annuloplasty ring modelled exclusively to fit the three-dimensional contours of the tricuspid valve's annulus.
Edwards takes two heart valve products to Europe:
Edwards Lifesciences has CE-marked for sale in Europe two heart valve therapy products - the Carpentier-Edwards PERIMOUNT Magna bioprosthesis and the Edwards MC3 tricuspid annuloplasty system. The PERIMOUNT Magna valve is the first pericardial heart valve specifically designed to optimise haemodynamics for an individual patient's anatomy, claims the Irvine, California firm. The MC3 device, the company adds, features a first-of-its-kind annuloplasty ring modelled exclusively to fit the three-dimensional contours of the tricuspid valve's annulus.
More from Archive
More from Medtech Insight
• By
Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.
• By
Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.
• By
A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.